Endpoints Editor John Carroll's

COVID-19 webinar series

Now that the full scope of the pandemic and the lockdowns are in full view, Endpoints is assembling 3 live action webinars on Zoom to discuss several critical aspects of what’s happening now.

Sign up for one or all, right here. And check out the links below for more details on these events. — John Carroll

April 28 / 2pm ET

Drug manufacturing in a time of coronavirus

The pandemic has roiled R&D plans, created new priorities overnight and generally forced a major shift in many global manufacturing operations. We’ll be talking to a group of the top manufacturing execs around the world about the new reality in their field.

How have they adapted in the face of the pandemic? And what’s ahead?

register to watch
COVID-19
Juan Andres

Juan Andres

Chief Technical Operations and Quality Officer
Moderna

As Chief Technical Operations and Quality Officer, Juan Andres is responsible for the supply of product required for Moderna’s preclinical and clinical development programs, as well as scaling the CMC (chemistry, manufacturing and controls) processes across Moderna’s portfolio. Mr. Andres also will lead all CMC late-stage development and future commercialization activities.

Mr. Andres was previously the Global Head of Technical Operations (Manufacturing and Supply Chain) for over 25,000 Novartis employees across all of its divisions. In this role, he had responsibility for all of Novartis’ manufacturing sites, and related support functions and technologies worldwide, overseeing small molecules drug substance and drug product, as well as biologics drug substance, drug product and technical development. Mr. Andres’ previous roles at Novartis included Group Novartis Quality Head, Global Head of Technical Research and Development, and Global Pharmaceutical Operations Head. Prior to Novartis, Mr. Andres worked at Eli Lilly & Co. for 18 years in a variety of manufacturing, production and quality roles in the United States, Puerto Rico, UK and Spain, most recently serving as Vice President, Pharmaceutical Manufacturing.

Mr. Andres holds a Master degree in Pharmacy from Alcala de Henares University in Madrid and completed an advanced development program at the London Business School.

Kay Schmidt

Kay Schmidt

Senior Vice President, Technical Operations
Catalent

Kay Schmidt was named Senior Vice President, Technical Operations of Catalent Pharma Solutions in February 2019. Ms. Schmidt joined Catalent in 2009, holding several leadership roles in product development across multiple drug delivery dosage forms. Most recently, she provided leadership to Catalent’s global virtual Project Management Organization for new product introductions, in addition to her role as Vice President, Product Development in the company’s Biologics and Specialty Drug Delivery business unit. Prior to joining Catalent, she held various leadership roles at GE Healthcare developing and delivering diagnostic imaging technologies. She is a certified Six Sigma Green Belt, and has a bachelor’s degree from Carroll University, Wisconsin and a master’s degree from the University of Wisconsin-Whitewater.

May 12 / 2pm ET

The new reality in biotech

Everyone in biopharma has had to deal with a new reality after the pandemic hit. Trial plans have been derailed, communications with staff have been disrupted, old schedules no longer apply. But through it all, biotech execs are getting things done. We’ll talk to a panel involving some of the most experienced vets in the business as they discuss managing a drug development operation in a radically different world.

register to watch
COVID-19

Presenting Sponsor

June 16 / 2pm ET

Dealmaking in a time of coronavirus

Contrary to what many people may have thought, the outbreak that has stymied so many organizations has pushed biopharma into overdrive on dealmaking. On top of the new alliances being formed for Covid-19, companies are also coming together on a long list of new projects related to core research areas.

What stage — discovery, early-, late- — is getting the most attention and how do you work terms on this new blizzard of deals being formed overnight?

COVID-19